Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks
- PMID: 28242844
- PMCID: PMC5498354
- DOI: 10.2215/CJN.10301016
Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks
Abstract
Survival analysis is commonly used to evaluate factors associated with time to an event of interest (e.g., ESRD, cardiovascular disease, and mortality) among CKD populations. Time to the event of interest is typically observed only for some participants. Other participants have their event time censored because of the end of the study, death, withdrawal from the study, or some other competing event. Classic survival analysis methods, such as Cox proportional hazards regression, rely on the assumption that any censoring is independent of the event of interest. However, in most clinical settings, such as in CKD populations, this assumption is unlikely to be true. For example, participants whose follow-up time is censored because of health-related death likely would have had a shorter time to ESRD, had they not died. These types of competing events that cause dependent censoring are referred to as competing risks. Here, we first describe common circumstances in clinical renal research where competing risks operate and then review statistical approaches for dealing with competing risks. We compare two of the most popular analytical methods used in settings of competing risks: cause-specific hazards models and the Fine and Gray approach (subdistribution hazards models). We also discuss practical recommendations for analysis and interpretation of survival data that incorporate competing risks. To demonstrate each of the analytical tools, we use a study of fibroblast growth factor 23 and risks of mortality and ESRD in participants with CKD from the Chronic Renal Insufficiency Cohort Study.
Keywords: Cardiovascular Diseases; Cause-specific; Chronic; Cox proportional hazards models; Cumulative incidence function; FGF-23; Fibroblast Growth Factors; Fibroblast growth factor 23; Follow-Up Studies; Kidney Failure; Proportional Hazards Models; Renal Insufficiency; Risk; Survival Analysis.
Copyright © 2017 by the American Society of Nephrology.
Figures





Similar articles
-
Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.Am J Kidney Dis. 2019 Dec;74(6):771-781. doi: 10.1053/j.ajkd.2019.05.026. Epub 2019 Aug 21. Am J Kidney Dis. 2019. PMID: 31445926 Free PMC article.
-
Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.Kidney Int. 2017 Mar;91(3):711-719. doi: 10.1016/j.kint.2016.10.021. Epub 2016 Dec 22. Kidney Int. 2017. PMID: 28017325 Free PMC article.
-
Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.Am J Kidney Dis. 2020 Jun;75(6):908-918. doi: 10.1053/j.ajkd.2019.09.009. Epub 2019 Dec 19. Am J Kidney Dis. 2020. PMID: 31864822 Free PMC article.
-
Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art.BMC Nephrol. 2014 Mar 14;15:45. doi: 10.1186/1471-2369-15-45. BMC Nephrol. 2014. PMID: 24628838 Free PMC article. Review.
-
Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease.Adv Chronic Kidney Dis. 2018 Mar;25(2):133-140. doi: 10.1053/j.ackd.2018.01.008. Adv Chronic Kidney Dis. 2018. PMID: 29580577 Review.
Cited by
-
Comparison of Associations of Food Security Instruments and Mediators With Premature All-Cause and Cardiovascular Disease Death in US Adults.Circ Cardiovasc Qual Outcomes. 2025 Feb;18(2):e011209. doi: 10.1161/CIRCOUTCOMES.124.011209. Epub 2025 Jan 9. Circ Cardiovasc Qual Outcomes. 2025. PMID: 39781770
-
Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD.PLoS One. 2020 Jan 31;15(1):e0228101. doi: 10.1371/journal.pone.0228101. eCollection 2020. PLoS One. 2020. PMID: 32004338 Free PMC article.
-
Competing mortality risks analysis of prediagnostic lifestyle and dietary factors in colorectal cancer survival: the Norwegian Women and Cancer Study.BMJ Open Gastroenterol. 2019 Oct 30;6(1):e000338. doi: 10.1136/bmjgast-2019-000338. eCollection 2019. BMJ Open Gastroenterol. 2019. PMID: 31749978 Free PMC article.
-
Association of Kidney Disease Quality of Life (KDQOL-36) with mortality and hospitalization in older adults receiving hemodialysis.BMC Nephrol. 2018 Jan 15;19(1):11. doi: 10.1186/s12882-017-0801-5. BMC Nephrol. 2018. PMID: 29334904 Free PMC article.
-
Prediction the prognosis of the poisoned patients undergoing hemodialysis using machine learning algorithms.BMC Med Inform Decis Mak. 2024 Feb 6;24(1):38. doi: 10.1186/s12911-024-02443-0. BMC Med Inform Decis Mak. 2024. PMID: 38321428 Free PMC article.
References
-
- Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432–2439, 2011 - PMC - PubMed
-
- Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z: Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 89: 886–896, 2016 - PubMed
-
- Ricardo AC, Lash JP, Fischer MJ, Lora CM, Budoff M, Keane MG, Kusek JW, Martinez M, Nessel L, Stamos T, Ojo A, Rahman M, Soliman EZ, Yang W, Feldman HI, Go AS; CRIC and HCRIC Investigators: Cardiovascular disease among hispanics and non-hispanics in the chronic renal insufficiency cohort (CRIC) study. Clin J Am Soc Nephrol 6: 2121–2131, 2011 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical